A common inflammatory arthritis brought on by persistently high uric acid levels in joints is called gout. One of the few rheumatological conditions that is curable is gout. It develops as a result of hyperuricemia-induced uric acid crystal deposition in joints. Typical observations include painful redness and swelling in the afflicted joints. As a result of rising living standards, the consumption of processed foods, the widespread use of medications that raise uric acid, and other factors, gout rates are rising, severely impairing people’s quality of life and placing a strain on global health systems. The typical range for uric acid levels is from 3.5 to 7.2 milligrams per deciliter (mg/dL), although this range can vary slightly depending on the laboratory. Higher levels of uric acid increase the risk of crystal formation. About 0.5% of individuals with uric acid levels between 7.0 and 8.9 mg/dL develop gout, while approximately 5% of those with uric acid levels exceeding 9 mg/dL are diagnosed with gout.
Drug classes (Anti-hyperuricemic Agents (Urate-Lowering Drugs), Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, and Other Drug Classes are used to segment the market for gout therapeutics. Antigout agents are another name for hyperuricemic agents. Anti-hyperuricemic drugs reduce blood uric acid levels by either inhibiting the synthesis of excess uric acid or accelerating the elimination of uric acid in the urine. Salicylates, pyrazinamide, ethambutol, nicotinic acid, cyclosporin, 2-ethylamino-1,3,4-thiadiazole, fructose, and cytotoxic agents are a few medications that might result in hyperuricemia. Xanthine oxidase inhibitors (allopurinol and febuxostat), uricases (pegloticase and rasburicase), and uricosuric medicines (benzbromarone, probenecid, and sulfinpyrazone) are some of the most often used pharmaceuticals in this area.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/gout-therapeutics-market/
Global Gout Therapeutics Market – Competitive Insight
In March 2022, Positive findings from a Phase 2a clinical trial of ABP-671, a randomized, double-blind, placebo-controlled treatment for persistent gout, were presented by Atom Bioscience.
In March 2022, Colchicine USP, 0.6 mg tablets from Strides Pharma were licensed by the US Food and Drug Administration to be used in the treatment and prevention of gout.
Some of the Key Players in the Global Gout Therapeutics Market Include –
- Ablynx
- Antares Pharma
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- CymaBay Therapeutics
- GlaxoSmithKline
- Horizon Pharma
- JW Pharmaceutical
- LG Life Sciences
- Merck
- Novartis
- Eisai
- Eli Lilly
- Novo Nordisk
Global Gout Therapeutics Market – Growth Drivers
The main causes of this growth are the rising incidence of gout and public knowledge of the disease’s treatment. In addition, the field has developed, and fresh therapeutic alternatives and a strong medication pipeline are propelling the field’s expansion even further. It is anticipated that these goods’ subsequent approval and release in the upcoming years will present a significant chance for market expansion. Through a variety of awareness initiatives, both public and private organizations work to increase public knowledge, which contributes to the expansion of space. Increasing urbanization and industrialization contribute to environmental stressors, propelling various health conditions. The global rise in Lifestyle disorders like Diabetes, Obesity, and Hypertension has led to increasing in number of gout cases. Age is also a major factor in people suffering from gout. The geriatric population contributes significantly to the growth of the Gout therapeutics market, as age-related factors can lead to increased Uric acid production and increased accumulation in various joints. The widespread use of different classes of drugs, such as Diuretics and nephrotoxic drugs has escalated the incidence of Complex gout cases, secondary gout in particular. Greater awareness among individuals about the symptoms and consequences of joint pain has led to an increased number of diagnoses followed by treatment regimens. Ongoing research and technological advancements in the field of rheumatology have led to the development of innovative treatments and therapies for gout approved by the authority. The government constantly updating the treatment of gout via various postmarket surveillance studies binds market companies to make new drugs.
Global Gout Therapeutics Market – Restraints
People should stop taking allopurinol and consult their doctor if they experience any side effects, such as a rash, nausea, headaches, or indigestion. People with kidney difficulties need to take lower doses and use extra caution while increasing doses because they are more likely to experience negative effects. Studies that are appropriate have not yet shown pediatric-specific issues that would restrict the efficacy of allopurinol in children whose elevated uric acid levels are related to cancer. NSAIDs and colchicine most frequently cause stomach and bowel issues, including as ulcers, diarrhea, nausea, vomiting, cramps, and abdominal pain. Reduced liver function, dermatitis, and nausea are among the side effects of Febuxostat. Steroids have numerous negative consequences when used to treat acute pain. However, delayed gout diagnosis among patients in developing and poor nations has hampered the market growth.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/gout-therapeutics-market/
Global Gout Therapeutics Market – Opportunities
The increasing global geriatric demographic presents a significant opportunity for Gout therapeutics, as age-related factors contribute to a higher prevalence of rheumatoid-related diseases including gout, creating a larger patient pool. Ongoing advancements in technology, such as the development of novel drug delivery systems and diagnostic tools, present opportunities for innovative solutions in the market for specializations of drugs for specific types or causes of gout. Growing awareness among consumers about health and the availability of effective treatment regimens given by the government creates opportunities for market expansion.
Global Gout Therapeutics Market – Geographical Insight
North America held a dominant revenue share of 47.81% in the global gout therapeutics market in 2022, primarily due to the presence of prominent companies, rising illness prevalence, and high disease awareness that resulted in high rates of diagnosis and treatment in the region. Additionally, the region’s anticipated introduction of new medications and improved access to healthcare will only serve to increase its market presence in the years to come. Regional Market Trends for Gout Therapeutics, 2023–2030. The United States leads the North American market, followed by Canada. The goal of several organizations, like the Gout & Uric Acid Education Society (GUAES), is to increase public knowledge of gout.
Global Gout Therapeutics Market – Key Development
- In March 2023, Selecta Biosciences, Inc. announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.
- in September 2022, Jiangsu HengRui Medicine Co., Ltd.’s SHR4640 was in a phase 3 trial to lower serum uric acid levels in patients. In addition, LG Chem’s LC350189, Shanton Pharma’s SAP-001, and InventisBio’s D-0120 are novel drugs under phase 2 trials,.
- On May 3, 2023, ENTOD pharmaceutical launched drops for inflammatory dry eye disease.